HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS

被引:32
作者
Girling, Alan [1 ]
Lilford, Richard [2 ]
Cole, Amanda [3 ]
Young, Terry [4 ]
机构
[1] Univ Birmingham, Inst Appl Hlth Res, Birmingham B15 2TT, W Midlands, England
[2] Univ Warwick, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England
[3] Off Hlth Econ, Berlin, Germany
[4] Brunel Univ, Sch Informat Syst Comp & Math, Uxbridge UB8 3PH, Middx, England
基金
英国工程与自然科学研究理事会;
关键词
Headroom analysis; Medical devices; Development decisions; INTEGRATING HEALTH ECONOMICS; PRODUCT DEVELOPMENT CYCLE; MEDICAL DEVICES; TECHNOLOGY-ASSESSMENT; DECISION-MAKING; UNCERTAINTY;
D O I
10.1017/S0266462315000501
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: The headroom approach to medical device development relies on the estimation of a value-based price ceiling at different stages of the development cycle. Such price-ceilings delineate the commercial opportunities for new products in many healthcare systems. We apply a simple model to obtain critical business information as the product proceeds along a development pathway, and indicate some future directions for the development of the approach. Methods: Health economic modelling in the supply-side development cycle for new products. Results: The headroom can be used: initially as a reality check' on the viability of the device in the healthcare market; to support product development decisions using a real options approach; and to contribute to a pricing policy which respects uncertainties in the reimbursement outlook. Conclusions: The headroom provides a unifying thread for business decisions along the development cycle for a new product. Over the course of the cycle attitudes to uncertainty will evolve, based on the timing and manner in which new information accrues. Within this framework the developmental value of new information can justify the costs of clinical trials and other evidence-gathering activities. Headroom can function as a simple shared tool to parties in commercial negotiations around individual products or groups of products. The development of similar approaches in other contexts holds promise for more rational planning of service provision.
引用
收藏
页码:331 / 338
页数:8
相关论文
共 25 条
  • [1] Expected value of sample information calculations in medical decision modeling
    Ades, AE
    Lu, G
    Claxton, K
    [J]. MEDICAL DECISION MAKING, 2004, 24 (02) : 207 - 227
  • [2] [Anonymous], 2010, BMJ-BRIT MED J, DOI DOI 10.1136/BMJ.C4413
  • [3] The development of health technology assessment
    Banta, D
    [J]. HEALTH POLICY, 2003, 63 (02) : 121 - 132
  • [4] Bartelmes M, 2009, GMS HLTH TECHNOL ASS, V5, P15
  • [5] Chapman AM, 2014, IFMBE Proceedings, V41, P1151, DOI [10.1007/978-3-319-00846-2_285, DOI 10.1007/978-3-319-00846-2_285]
  • [6] OFT, VBP: QED?
    Claxton, Karl
    [J]. HEALTH ECONOMICS, 2007, 16 (06) : 545 - 558
  • [7] CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
    Claxton, Karl
    Sculpher, Mark
    Palmer, Stephen
    Culyer, Anthony J.
    [J]. HEALTH ECONOMICS, 2015, 24 (01) : 1 - 7
  • [8] Cosh E., 2007, Journal of Commercial Biotechnology, V13, P263, DOI [DOI 10.1057/PALGRAVE.JCB.3050062, 10.1057/palgrave.jcb.3050062]
  • [9] Dixit K., 1994, INVESTMENT UNCERTAIN
  • [10] Early-Stage Valuation of Medical Devices: The Role of Developmental Uncertainty
    Girling, Alan
    Young, Terry
    Brown, Celia
    Lilford, Richard
    [J]. VALUE IN HEALTH, 2010, 13 (05) : 585 - 591